Drugs in Dev. Cardiology/Vascular Diseases
Phase I
Germany 
Lead Product(s) : TLC-2716
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : OrsoBio
Deal Size : Undisclosed
Deal Type : Acquisition
Details : TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal ...
Product Name : TLC-2716
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 11, 2022
Lead Product(s) : TLC-2716
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : OrsoBio
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : INKEF Capital
Deal Size : $76.0 million
Deal Type : Series B Financing
Details : The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program, CDR132L and the expansion of the company’s earlier-stage pipeline.
Product Name : CDR132L
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
August 25, 2021
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : INKEF Capital
Deal Size : $76.0 million
Deal Type : Series B Financing
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.
Product Name : CDR132L
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.
Product Name : CDR132L
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 22, 2020
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L
Details : In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.
Product Name : CDR132L
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 31, 2020
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
